Skip to content

Molecular Characterization of Primary Mucosal Melanoma

Molecular Characterization of Primary Mucosal Melanoma

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03319693
Acronym
MELMUQ
Enrollment
65
Registered
2017-10-24
Start date
2017-08-28
Completion date
2021-04-28
Last updated
2024-08-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Mucosal Melanoma

Brief summary

Primary mucosal melanomas (MPM) are rarer than cutaneous melanomas, but also more severe. They are usually refractory to conventional approaches, regularly excluded from major therapeutic programs and not sensitive to new targeted therapies orphans. The identification of therapeutic targets and accessibility to existing, developing or future targeted therapies improves the survival of patients with MPM. The principal goal is to describe, using a large panel of genes, the prevalence of major mutations in a cohort of MPMs based on the population of a French region.

Interventions

GENETICSomatic Genetic

NGS analysis

Sponsors

CHU de Reims
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Incident Mucosal melanoma in the Champagne-Ardenne region 2004-2014

Exclusion criteria

* Cutaneous melanoma * Uveal melanoma

Design outcomes

Primary

MeasureTime frameDescription
The frequency of main mutations identified using the NGS panelDay 0NGS panel

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026